Bio­gen spells out re­mark­able ef­fi­ca­cy da­ta in Alzheimer's for ad­u­canum­ab, but safe­ty threat per­sists

Shares of Bio­gen jumped Thurs­day af­ter­noon af­ter an up­dat­ed as­sess­ment of the re­mark­ably pos­i­tive da­ta they’ve been col­lect­ing from the PRIME study of their Alzheimer’s drug hope­ful ad­u­canum­ab was leaked among in­vestors and then quick­ly spread on­line.

Aside from the ker­fuf­fle over how the da­ta first be­gan to sur­face, a close look at the full set of re­sults re­vealed a sur­pris­ing­ly pos­i­tive read­out that will help ig­nite re­newed en­thu­si­asm for Bio­gen’s prospects in what is per­haps the tough­est field in R&D — though a big safe­ty is­sue re­mains a key con­cern.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN